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NIH is preparing to announce plans for the pilot phase of their proposed Human Cancer 
Genome Project. This initiative seeks to provide a complete list of the mutations that give 
rise to cancer.Two institutes at the National Institutes 
of Health (NIH) have linked arms to go 
after cancer in a big way. Inspired by 
the successes of drugs like Gleevec, 
Herceptin, and Iressa—therapies tar­
geted to specific changes in the DNA 
of tumors—the National Cancer Insti­
tute (NCI) and the National Human 
Genome Research Institute (NHGRI) 
are considering an ambitious project 
to systematically find all genetic altera­
tions in the major types of cancer. The 
idea itself is not new as a handful of 
research groups are already conduct­
ing similar activities, but the NIH project 
would bring the scale and speed of 
discovery to a new level.
The initiative—dubbed the Human 
Cancer Genome Project (HCGP)—is 
expected to begin in 2006 with a 3 
year pilot project, plans for which will 
be announced in the next few weeks. 
Although NCI and NHGRI are provid­
ing few details prior to the announce­
ment, the two institutes are expected 
to solicit applications from different 
research groups to carry out a vari­
ety of projects—from collecting tumor 
samples and sequencing DNA to 
developing new technologies for ana­
lyzing the genome. Together these 
projects will help to unearth new can­
cer genes and possible drug targets in 
a discrete set of tumor types. In July 
2005, a workshop entitled “Toward a 
Comprehensive Genomic Analysis of 
Cancer” was convened by NCI and 
NHGRI to seek input on the HCGP 
from the scientific community. Par­
ticipants agreed that a pilot phase 
was needed “to attack this enormous 
problem with multiple projects that 
use a range of genomic technologies 
coordinated around the same sam­
ples,” according to a recently released 
report from the workshop (http://cgap.
nci.nih.gov/Info/TCGA_executive_ 
summary.pdf).As NCI and NHGRI officials continue 
to hammer out the precise plan for 
this pilot phase, genome aficionados 
say that results from their own stud­
ies bode well for the proposed HCGP. 
“In a way, we and other people have 
already done small pilot projects to 
show [this approach] is worthwhile,” 
says Victor Velculescu, a researcher at 
the Johns Hopkins University Kimmel 
Cancer Center.
For decades, the traditional app­
roach to identify cancer genes was to 
hand­pick likely candidates and then 
search for mutations within them. 
But since the completion of the draft 
human genome sequence in 2000, 
scientists have had the tools to go 
after cancer mutations in a more glo­
bal and systematic way. “The approach 
of mapping cancer genes has almost 
been saturated. All low hanging fruits 
have already been taken,” says Richard 
Wooster. Along with Michael Stratten 
and Andrew Futreal, Wooster leads 
the Cancer Genome Project at the 
Wellcome Trust Sanger Institute in the 
UK, a project that started in April 2000 
and is similar in scope to that planned 
by the NIH. “We have a good dialogue 
with the NCI/NHGRI and see this very 
much as a collaborative effort,” says 
Wooster. “There is a strong history 
of the NIH working with Sanger. The 
Sanger sequenced one third of the 
human genome with the NIH in the 
public effort.”
Scientists of the post­genome era 
can examine the sequences of thou­
sands of genes in cancer cells. But 
because of the expense and techni­
cal limitations of current sequencing 
technologies, groups like the Sanger’s 
have, for now, been focusing on spe­
cific sets of genes rather than attempt­
ing to go after all of them at once. “We 
have initially focused on the more likely 
candidates and then will move to less Cell 123, Delikely ones and eventually to those 
genes for which there is no known 
function,” says Wooster.
The Sanger group first opted to 
home in on genes that act in certain 
pathways, such as the one involving 
the infamous ras oncogene, which is 
mutated in many cancers. The strat­
egy paid off and in 2002 the group dis­
covered a gene, called BRAF, that is 
mutated in 66% of malignant melano­
mas and at a lower frequency in a wide 
range of other human cancers. The 
Sanger is now collaborating with the 
UK’s Institute for Cancer Research, a 
private research institute based in Lon­
don, to develop compounds to target 
this mutation.
A similar approach was independ­
ently adopted by Johns Hopkins 
University scientists, who had been 
working for many years on the genet­
ics of colon cancer. “We were the 
first to start looking at gene families 
in a systematic way, starting with the 
tyrosine kinases in colon cancer,” says 
Velculescu. “And we made an effort 
to be comprehensive in our search.” 
In 2004, they discovered PIK3CA, a 
gene that is mutated in about 30% of 
all human cancers that had somehow 
slipped through the fingers of cancer 
researchers until then.
The kinase family of proteins has 
been a favorite among cancer gene 
hunters because these enzymes medi­
ate the signals that tell a cell to grow 
or stop growing, processes that go 
awry in cancer cells. In addition, one 
of the most successful modern cancer 
drugs, Gleevec (imatinib mesylate), 
targets a kinase. “If we can find more 
kinase mutations, drug companies 
will already know how to make drugs 
against them,” says Matthew Meyer­
son of the Dana­Farber Cancer Insti­
tute in Boston.
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versity in St. Louis have cast a wider net 
to fish out cancer mutations. They first 
selected several interesting pathways 
and gene families and then identified 
genes within them that are specifically 
expressed in their cancer of interest, 
a type of leukemia called AML. “For 
example, out of the long list of recep­
tor tyrosine kinases only a small frac­
tion is expressed in AML cells, so we 
reasoned it would be most produc­
tive to only sequence those genes,” 
says Timothy J. Ley, who collaborates 
with Rick Wilson, the director of the 
Genome Sequencing Center at Wash­
ington University. To add to the list of 
possible candidates to sequence, the 
researchers also used a technique to 
find small deletions and amplifications 
throughout cancer genomes, which 
may flag the positions of possible can­
cer genes.
As the speed with which DNA can 
be sequenced increases and costs 
decrease, it may be possible in a few 
years to sequence every gene in every 
cancer. “It makes absolute sense [to 
do that eventually],” says Meyerson. 
“We don’t know enough about the 
process to say which genes could be 
involved. It could be that non­coding 
genes or even non­transcribed genes 
play a role [in cancer].” But for now 
most researchers say a more selective 
approach is their best bet. “We don’t 
need every gene sequence. Of course 
there will be endless arguments about 
which genes to focus on,” says NCI 
researcher Louis Staudt, who studies 
lymphoma.
DNA sequencing, although a major 
component, is only one part of the 
process of finding cancer mutations. 
“There are many ways to create a 
tumor,” says Meyerson. “So you need 
more than one approach to look for 
alterations in the DNA.” Indeed can­
cers can arise from small mutations 
in the DNA sequences, changes 
in the number of copies of specific 
genes, rearrangements affecting 
entire chromosomes, and even from 
tumor viruses that land inside or next 
to human genes. “The only way to 
move forward is to do whole genome 
expression studies and copy number 
and gene loss assays—which are fairly 
easy to do—as well as obtaining the 736 Cell 123, December 2, 2005 ©2005 Esequence information on a subset of 
human genes,” says Staudt. “These 
approaches need to proceed in paral­
lel. And then perhaps you also need 
to look at epigenetic changes.” (Epige­
netic changes—heritable changes in 
genome function that do not alter the 
DNA sequence—are also thought to 
be players in cancer.)
Meyerson’s group, in collaboration 
with that of William Sellers (who has 
just left his post at the Dana­Farber to 
become head of oncology research for 
the pharmaceutical giant Novartis), has 
been using a combination of sequenc­
ing and “SNP arrays” to find cancer 
genes. SNP array technology ena­
bles researchers to look for changes 
in the number of copies of specific 
genes across the entire genome. 
This approach identified a gene that 
is amplified in melanoma, especially 
in metastatic disease, showing that 
genomics can be useful not only to 
develop therapies but also for deter­
mining disease prognosis.
In addition to taking advantage of 
different approaches scientists need 
to “validate potential drug targets as 
part of [their] screening program,” says 
Robert L. Strausberg, vice president 
for human genomic medicine at the 
J. Craig Venter Institute in Rockville, 
Maryland. His group collaborates with 
Greg Riggins at Johns Hopkins Uni­
versity and Lloyd Old and Andy Simp­
son at the Ludwig Institute for Can­
cer Research in New York City to do 
just that. Strausberg’s team looks for 
genomic changes in tumors, whereas 
the Hopkins and Ludwig teams evalu­
ate potential targets and test possible 
therapies by way of small molecules 
and antibodies. “Both Hopkins and 
the Ludwig can do early clinical trials,” 
explains Strausberg, who believes that 
a greater involvement of academic sci­
entists in the early stages of the drug 
development process would produce 
a higher number of hits. “It is important 
to provide resources to both academic 
and industrial scientists to help build 
truly integrated partnerships, quite dis­
tinct from the traditional view of trans­
lational research,” he adds.
The translation of cancer mutations 
into cancer therapies is the driving 
goal of HCGP and similar projects. But lsevier Inc.some feel the challenge is insurmount­
able. “If you have a type of tumor that 
has a stable genome, such as some 
leukemias, it is possible to cure it by 
targeting one mutation,” says Garth R. 
Anderson of the Roswell Park Cancer 
Institute in Buffalo, New York. “But in 
most adult solid tumors the genome 
is shot to hell by the time the tumor 
is found. Even if you find genes like 
BRAF, the mutation will not be in every 
cell [in the tumor].”
The large variation in molecular 
changes from one tumor to another, 
and even within the same tumor from 
one cell to another, has long been an 
obstacle for the development of effec­
tive therapies. A recent study by the 
Sanger group provided the first clear 
demonstration of the vast array of 
mutations present in cancer cells. The 
study, which generated over 40 mil­
lion bases of DNA sequence, identi­
fied close to 200 mutations in protein 
kinase genes in lung tumors, indicat­
ing that many mutated protein kinases 
may be contributing to lung cancer 
development but that mutations in any 
one gene are infrequent. “For some 
tumors we will find high frequency 
mutations that will make good drug 
targets, but many will be a mixture 
of different low frequency mutations,” 
says Wooster. He adds, however, that 
this information is still useful “because 
it informs the drug companies as to 
what the cancer cell world looks like 
and how to develop better therapies.”
To many cancer specialists, this 
kind of molecular characterization 
of tumors is what is needed to move 
the field forward. “We have already 
gotten so much mileage out of single 
molecular abnormalities. This gives 
us great encouragement to continue 
with the approach,” says Larry Nor­
ton, a breast­oncologist at the Memo­
rial Sloan­Kettering Cancer Center in 
New York City and chair of the medical 
board of The Breast Cancer Research 
Foundation. “Speaking on behalf of the 
therapeutic community, I am very sup­
portive of the [HCGP] initiative. Even if 
you cannot find therapies it will help us 
determine prognosis and how to bet­
ter treat patients,” he adds.
The identification of genes that are 
mutated in cancer is likely to have rip­
ple­down effects in all areas of can­
cer research. “We cannot predict at 
this stage all that will come from [the 
HCGP], but we are excited about 
it because it might help us with our 
own work,” says Judah Folkman, a 
researcher at Childrens’ Hospital Bos­
ton, renowned for developing drugs 
to cut off the blood and nutrient sup­
ply to tumors. At the moment, no one 
knows what switches on the abnormal 
sprouting of blood vessels that feeds 
tumor growth. “We hope that the can­
cer genome project will help us find 
the genes responsible for controlling 
the switch,” says Folkman.
Despite the encouragement expressed 
by many cancer researchers, most agree 
that gathering and interpreting massive 
amounts of sequence data and inte­
grating it with other kinds of genomics 
information will not be easy. By one esti­
mate, the amount of sequencing alone 
required for the HCGP will be equivalent 
to doing about 150 Human Genome 
Projects. Beyond the challenge of 
obtaining accurate DNA sequence on 
such a large scale, researchers will have 
to sift through the hundreds of changes 
identified in any one set of genes and 
determine which are specific to cancer 
and which are normal changes that 
occur in the DNA of any individual (in 
other words, polymorphisms).
Ley, Wilson, and colleagues add­
ressed this problem by comparing each 
cancer sequence to that of DNA taken 
from skin cells of the same patient—
polymorphisms should be present in both samples whereas cancer­specific 
changes should be present only in the 
cancer DNA. “Until massive numbers 
of genomes are sequenced so that 
we have a database of all polymor­
phisms, including rare ones, you have 
to compare tumor versus germline in 
the same patient,” says Ley. “You need 
to anticipate this problem and design 
your experiments to overcome it, even 
if it will require more effort.”
Another potential stumbling block 
is obtaining cancer DNA that is suf­
ficiently pure (in other words, free of 
DNA from normal cells) and in large 
enough quantities. Scientists who are 
doing this work say they have spent 
up to several years finessing tech­
niques to produce tumor databases 
with the required quality and quantity 
of genomic DNA.
These kinds of issues will be cru­
cial, scientists say, to the success 
of the HCGP pilot project, expected 
to start in 2006. If all goes well, full­
scale implementation of the HCGP, 
which would include as many as 50 
tumor types, should begin in 2009 
and last until 2014. This timeline (along 
with preliminary details about the 
project) was determined by a work­
ing group of NCI’s Cancer Genome 
Anatomy Project, co­chaired by Fred 
Hutchinson Cancer Research Center 
president Leland Hartwell and Broad 
Institute director Eric Lander, which 
presented its recommendations in 
February 2005. (Their proposal is 
available at http://www.genome.gov/Cell 123, DePages/About/NACHGR/May2005 
NACHGRAgenda/ReportoftheWorking 
GrouponBiomedicalTechnology.pdf.)
NCI and NHGRI have each com­
mitted $50 million to the 3 year pilot 
project, pending approval from their 
respective scientific advisory boards 
and council. But the full price tag of 
the project, or where the rest of the 
money will come from, has not yet 
been revealed. The original proposal 
for the full­scale HCGP estimated that 
today the project would cost $12.5 bil­
lion, but by the time it actually takes 
off, assuming that sequencing tech­
nologies continue to become cheaper, 
the price tag would be about $1.3 bil­
lion. The potential expense has many 
scientists worried that the project will 
take funds away from individual grants 
at a time of tight funding, but support­
ers say that is not the intent. “In terms 
of vision, the scientists who support 
this project are seeing it as an addi­
tional resource rather than taking away 
money from available funds,” says 
Meyerson.
Earlier this year, NCI director Andrew 
C. von Eschenbach (who in Septem­
ber took on the additional duties of 
acting commissioner for the U.S. Food 
and Drug Administration) set the goal 
of eliminating suffering and death due 
to cancer by 2015. Whether projects 
like the HCGP and other NCI initiatives 
will bring us closer to that goal remains 
to be seen. But for now, scientists are 
cautiously optimistic about what the 
HCGP gene hunt will produce.
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